Larazotide
CAS 258818-34-7
Larazotide research shows why testing an intestinal barrier is different from testing a clinical outcome.
Read on chemBlink: https://www.chemblink.com/en/products/258818-34-7.htm
Larazotide is a short peptide investigated in celiac disease through a question about intestinal barriers. Cells meet at tight junctions, which help control passage between them. The hypothesis concerned this route, not destruction of gluten in food. An experiment that tracks passage of a probe tests a different outcome from a study asking whether people's symptoms improve. Early controlled studies used larazotide acetate during gluten challenge, while the CAS entry identifies the peptide. A later phase 3 trial was discontinued after an analysis indicated that too much additional enrollment would be needed to support continuation. The research illustrates why a plausible mechanism and an exploratory result cannot substitute for confirmatory evidence. It does not establish the peptide as a replacement for dietary management.
Published:
2026-11-11